Unknown

Dataset Information

0

Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.


ABSTRACT: There is no widely accepted standard for antifungal prophylaxis in patients with hematologic malignancies. The Infectious Diseases Working Party of the German Society for Haematology and Oncology assigned a committee of hematologists and infectious disease specialists to develop recommendations. Literature data bases were systematically searched for clinical trials on antifungal prophylaxis. The studies identified were shared within the committee. Data were extracted by two of the authors (OAC and MSi). The consensus process was conducted by email communication. Finally, a review committee discussed the proposed recommendations. After consensus was established the recommendations were finalized. A total of 86 trials were identified including 16,922 patients. Only a few trials yielded significant differences in efficacy. Fluconazole 400 mg/d improved the incidence rates of invasive fungal infections and attributable mortality in allogeneic stem cell recipients. Posaconazole 600 mg/d reduced the incidence of IFI and attributable mortality in allogeneic stem cell recipients with severe graft versus host disease, and in patients with acute myelogenous leukemia or myelodysplastic syndrome additionally reduced overall mortality. Aerosolized liposomal amphotericin B reduced the incidence rate of invasive pulmonary aspergillosis. Posaconazole 600 mg/d is recommended in patients with acute myelogenous leukemia/myelodysplastic syndrome or undergoing allogeneic stem cell recipients with graft versus host disease for the prevention of invasive fungal infections and attributable mortality (Level A I). Fluconazole 400 mg/d is recommended in allogeneic stem cell recipients until development of graft versus host disease only (Level A I). Aerosolized liposomal amphotericin B is recommended during prolonged neutropenia (Level B II).

SUBMITTER: Cornely OA 

PROVIDER: S-EPMC2625427 | biostudies-literature | 2009 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.

Cornely Oliver A OA   Böhme Angelika A   Buchheidt Dieter D   Einsele Hermann H   Heinz Werner J WJ   Karthaus Meinolf M   Krause Stefan W SW   Krüger William W   Maschmeyer Georg G   Penack Olaf O   Ritter Jörg J   Ruhnke Markus M   Sandherr Michael M   Sieniawski Michal M   Vehreschild Jörg-Janne JJ   Wolf Hans-Heinrich HH   Ullmann Andrew J AJ  

Haematologica 20081209 1


There is no widely accepted standard for antifungal prophylaxis in patients with hematologic malignancies. The Infectious Diseases Working Party of the German Society for Haematology and Oncology assigned a committee of hematologists and infectious disease specialists to develop recommendations. Literature data bases were systematically searched for clinical trials on antifungal prophylaxis. The studies identified were shared within the committee. Data were extracted by two of the authors (OAC a  ...[more]

Similar Datasets

| S-EPMC5754425 | biostudies-literature
| S-EPMC10393896 | biostudies-literature
| S-EPMC8116237 | biostudies-literature
| S-EPMC6005139 | biostudies-literature
| S-EPMC8230401 | biostudies-literature
| S-EPMC7505554 | biostudies-literature
| S-EPMC8666647 | biostudies-literature
| S-EPMC4922317 | biostudies-literature
| S-EPMC5645428 | biostudies-literature
| S-EPMC4269340 | biostudies-literature